Seizert Capital Partners LLC lessened its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 6.8% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 604,306 shares of the biopharmaceutical company’s stock after selling 43,877 shares during the quarter. Gilead Sciences comprises about 2.0% of Seizert Capital Partners LLC’s holdings, making the stock its 19th largest position. Seizert Capital Partners LLC’s holdings in Gilead Sciences were worth $40,827,000 at the end of the most recent reporting period.
Other hedge funds have also recently added to or reduced their stakes in the company. Advisors Preferred LLC purchased a new stake in shares of Gilead Sciences during the 2nd quarter valued at approximately $26,000. Creative Financial Designs Inc. ADV raised its position in Gilead Sciences by 55.9% in the first quarter. Creative Financial Designs Inc. ADV now owns 460 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 165 shares during the period. Trustcore Financial Services LLC purchased a new stake in Gilead Sciences in the first quarter valued at approximately $34,000. Weaver Consulting Group purchased a new stake in Gilead Sciences in the first quarter valued at approximately $34,000. Finally, Legacy Advisors LLC purchased a new stake in Gilead Sciences in the second quarter valued at approximately $37,000. 78.78% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NASDAQ:GILD traded down $1.71 during trading on Friday, hitting $62.51. The company’s stock had a trading volume of 5,445,326 shares, compared to its average volume of 6,092,799. The business has a 50 day moving average price of $65.54 and a two-hundred day moving average price of $65.74. The company has a market capitalization of $81.22 billion, a PE ratio of 10.16, a P/E/G ratio of 3.04 and a beta of 1.16. The company has a debt-to-equity ratio of 1.13, a quick ratio of 3.67 and a current ratio of 3.76. Gilead Sciences, Inc. has a fifty-two week low of $60.32 and a fifty-two week high of $79.61.
The firm also recently declared a quarterly dividend, which will be paid on Friday, September 27th. Shareholders of record on Friday, September 13th will be paid a $0.63 dividend. The ex-dividend date is Thursday, September 12th. This represents a $2.52 annualized dividend and a dividend yield of 4.03%. Gilead Sciences’s dividend payout ratio (DPR) is 40.98%.
GILD has been the topic of a number of research analyst reports. Goldman Sachs Group lowered Gilead Sciences from a “neutral” rating to a “sell” rating and cut their target price for the company from $70.00 to $60.00 in a research report on Tuesday, May 28th. Raymond James boosted their target price on Gilead Sciences from $83.00 to $86.00 and gave the company a “strong-buy” rating in a research report on Wednesday, July 31st. ValuEngine raised Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. BidaskClub lowered Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday, June 5th. Finally, Oppenheimer set a $85.00 target price on Gilead Sciences and gave the company a “buy” rating in a research report on Friday, July 12th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have issued a buy rating and two have assigned a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $82.29.
In other Gilead Sciences news, EVP Brett A. Pletcher sold 608 shares of the business’s stock in a transaction on Monday, August 19th. The shares were sold at an average price of $64.35, for a total value of $39,124.80. Following the completion of the transaction, the executive vice president now owns 27,198 shares in the company, valued at $1,750,191.30. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Brett A. Pletcher sold 5,816 shares of the business’s stock in a transaction on Tuesday, June 18th. The stock was sold at an average price of $68.75, for a total transaction of $399,850.00. Following the completion of the transaction, the executive vice president now owns 27,198 shares of the company’s stock, valued at approximately $1,869,862.50. The disclosure for this sale can be found here. In the last 90 days, insiders sold 13,624 shares of company stock valued at $907,479. Insiders own 0.20% of the company’s stock.
About Gilead Sciences
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Featured Article: How to Profit and Limit Losses With Stop Orders
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.